Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06477107

A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion

This study is being done to examine whether transcranial direct current stimulation (tDCS) will increase cerebral blood flow which may provide a clinical benefit such as improving cognitive impairment.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Vasculopathy leading to imaging evidence of hypoperfusion
  • Cognitive impairment

Exclusion criteria

  • Pregnancy
  • Contraindication to MRI or tDCS including metallic implanted objects.
  • Medical instability or inability to cooperate during the study as assessed by the treating physician to participate in the study.

Treatment and study plan

Soterix® 4x1HD-TDCS

Device

Is intended for inducing cortical neuromodulation for research and treatment purposes.

Soterix® 1x1 tDCS

Device

At-home remotely supervised transcranial direct current stimulation (tDCS) at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and automatic turn off once it reaches the maximal intensity.

Cognitive Training Program

Behavioral

Computerized cognitive therapy for 45 minutes per day that starts at the same time with stimulation

Primary outcomes

  1. Changes in cerebral blood flow

    Time frame: Phase 1 Day 0 and Phase 2 Day 0, 14, 44, and 58

    Cerebral blood flow imaging assessed by MRI to measure blood flow through the blood vessels reported in millimeters of mercury (mmHg)

Secondary outcomes

  1. Change in cognitive impairment

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Montreal Cognitive Assessment (MoCA), which is a 30-item questionnaire that includes tests of orientation, attention, memory, language and visual-spatial skills. Possible total scores range from 0 to 30, with higher scores indicating higher cognitive function. A final total score of 26 and above is consider normal.

  2. Change in Fatigue Severity Scale (FFS)

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Fatigue Severity Scale (FFS) 9-item questionnaire that contains statements that rate fatigue symptoms on a scale of 1 to 7 where a low value (e.g., 1) indicates strong disagreement with the statement and a high value (e.g., 7) indicates strong agreement. Possible total scores range from 9 to 63, with higher scores indicating greater fatigue severity.

  3. Change in Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F)

    Time frame: Phase I Day 0, Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) 18-item questionnaire that rates how a subject is currently feeling in regards to fatigue symptoms on a scale of 0 to 10 where a low value (e.g., 0) indicates "not at all/no effort at all" and a high value (e.g., 10) indicates "extremely/tremendous chore". Possible total scores range from 0 to 180, with higher scores indicating greater fatigue severity.

  4. Change in Stroke Specific Quality of Life (SS-QOL)

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Stroke Specific Quality of Life (SS-QOL) 49-item questionnaire assessing quality of life with regards to energy, family roles, language, mobility, mood, personality, self-care, social roles, thinking, upper extremity function, vision, and work/productivity on a scale of 1 to 5 where a low value (e.g., 1) indicates "total help/couldn't do it at all/strongly agree" and a high value (e.g., 5) indicates "no help needed/no trouble at all/strongly disagree". Possible total scores range from 49 to 245, with higher scores indicating better quality of life.

  5. Change in depression severity

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Patient Health Questionnaire 9-item (PHQ-9) scale to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the nine items ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression.

  6. Change in sleepiness

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Epworth sleepiness scale (ESS) 8-item questionnaire that measures daytime sleepiness in participants. Possible scores range from 0-24, with higher scores indicating a higher average sleep propensity in daily life, and a worse outcome.

  7. Change in trail making test

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    The Trail Making Test is a two part assessment of cognitive functions, principally attention and working memory. Subjects connect a set of 25 dots as quickly as possible, connect 13 dots labeled alphabetically, and 12 dots that are numbered in an alternating pattern as quickly as possible without lifting the pen. Results are reported as the number of seconds required to complete the task with higher scores indicating greater impairment.

  8. Change in memory task

    Time frame: Phase 2 Days 0, 14±3, 44±7, and 58±14, 72±14

    Assessed using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) wordlist memory test (WLT). This is a memory task for assessing word list recall. A list of 10 words are read 3 times and subjects are asked to recall the list of words. The more words recalled indicates less cognitive impairment.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Augmenting Cerebral Perfusion With Transcranial Direct Current Stimulation (tDCS) in Chronic Hypoperfusion States

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 27, 2024
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.